222 related articles for article (PubMed ID: 30967419)
1. Survival Following Chemotherapy in Ovarian Clear Cell Carcinoma Is Not Associated with Pathological Misclassification of Tumor Histotype.
Takenaka M; Köbel M; Garsed DW; Fereday S; Pandey A; Etemadmoghadam D; Hendley J; Kawabata A; Noguchi D; Yanaihara N; Takahashi H; Kiyokawa T; Ikegami M; Takano H; Isonishi S; Ochiai K; Traficante N; Gadipally S; Semple T; Vassiliadis D; Amarasinghe K; Li J; Mir Arnau G; Okamoto A; Friedlander M; Bowtell DDL;
Clin Cancer Res; 2019 Jul; 25(13):3962-3973. PubMed ID: 30967419
[TBL] [Abstract][Full Text] [Related]
2. An evaluation of progression free survival and overall survival of ovarian cancer patients with clear cell carcinoma versus serous carcinoma treated with platinum therapy: An NRG Oncology/Gynecologic Oncology Group experience.
Oliver KE; Brady WE; Birrer M; Gershenson DM; Fleming G; Copeland LJ; Tewari K; Argenta PA; Mannel RS; Secord AA; Stephan JM; Mutch DG; Stehman FB; Muggia FM; Rose PG; Armstrong DK; Bookman MA; Burger RA; Farley JH
Gynecol Oncol; 2017 Nov; 147(2):243-249. PubMed ID: 28807367
[TBL] [Abstract][Full Text] [Related]
3. The clinical characteristics and outcomes of cases with pure ovarian clear cell, mixed type and high-grade serous adenocarcinoma.
Kucukgoz Gulec U; Paydas S; Guzel AB; Vardar MA; Khatib G; Gumurdulu D
Arch Gynecol Obstet; 2015 Oct; 292(4):923-9. PubMed ID: 25855053
[TBL] [Abstract][Full Text] [Related]
4. Advanced stage clear-cell epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience.
Pectasides D; Fountzilas G; Aravantinos G; Kalofonos C; Efstathiou H; Farmakis D; Skarlos D; Pavlidis N; Economopoulos T; Dimopoulos MA
Gynecol Oncol; 2006 Aug; 102(2):285-91. PubMed ID: 16516283
[TBL] [Abstract][Full Text] [Related]
5. Genomic profiling of ovarian clear cell carcinoma in Chinese patients reveals potential prognostic biomarkers for survival.
Ye S; Zhou S; Wu Y; Pei X; Jiang W; Shi W; Yang W; Zhou X; Shan B; Yang H
Ann Med; 2023 Dec; 55(1):2218104. PubMed ID: 37272300
[TBL] [Abstract][Full Text] [Related]
6. Adjuvant chemotherapy in patients with stage I endometrioid or clear cell ovarian cancer in the platinum era: a Surveillance, Epidemiology, and End Results Cohort Study, 2000-2013.
Oseledchyk A; Leitao MM; Konner J; O'Cearbhaill RE; Zamarin D; Sonoda Y; Gardner GJ; Long Roche K; Aghajanian CA; Grisham RN; Brown CL; Snyder A; Chi DS; Soslow RA; Abu-Rustum NR; Zivanovic O
Ann Oncol; 2017 Dec; 28(12):2985-2993. PubMed ID: 28950307
[TBL] [Abstract][Full Text] [Related]
7. Effect of Chemotherapy, Laparoscopy, and Cytology on Stage IC Ovarian Clear Cell Carcinoma: A Long-Term, Single-Center Study.
Chang HT; Chiu ML; Wang TY; Chen TC; Chang CL; Su TH; Wang KG; Wang KL; Yang YC; Chen JR
Int J Environ Res Public Health; 2020 Jan; 17(2):. PubMed ID: 31940991
[TBL] [Abstract][Full Text] [Related]
8. Three versus six cycles of adjuvant platinum-based chemotherapy in early stage clear cell ovarian carcinoma - A multi-institutional cohort.
Prendergast EN; Holzapfel M; Mueller JJ; Leitao MM; Gunderson CC; Moore KN; Erickson BK; Leath CA; Diaz Moore ES; Cohen JG; Walsh CS
Gynecol Oncol; 2017 Feb; 144(2):274-278. PubMed ID: 27979319
[TBL] [Abstract][Full Text] [Related]
9. Ovarian clear cell carcinoma, outcomes by stage: the MSK experience.
Shu CA; Zhou Q; Jotwani AR; Iasonos A; Leitao MM; Konner JA; Aghajanian CA
Gynecol Oncol; 2015 Nov; 139(2):236-41. PubMed ID: 26404183
[TBL] [Abstract][Full Text] [Related]
10. Clinical outcome of the ovarian clear cell carcinoma compared to other epithelial ovarian cancers when treated with paclitaxel and carboplatin.
Sirichaisutdhikorn D; Suprasert P; Khunamornpong S
Asian Pac J Cancer Prev; 2009; 10(6):1041-5. PubMed ID: 20192580
[TBL] [Abstract][Full Text] [Related]
11. Is the presence of endometriosis associated with a survival benefit in pure ovarian clear cell carcinoma?
Sahin H; Sari ME; Cuylan ZF; Haberal AN; Sirvan L; Coban G; Yalcin I; Güngör T; Celik H; Meydanli MM; Ayhan A
Arch Gynecol Obstet; 2018 Apr; 297(4):1005-1013. PubMed ID: 29383437
[TBL] [Abstract][Full Text] [Related]
12. A Clinical and Molecular Phase II Trial of Oral ENMD-2076 in Ovarian Clear Cell Carcinoma (OCCC): A Study of the Princess Margaret Phase II Consortium.
Lheureux S; Tinker A; Clarke B; Ghatage P; Welch S; Weberpals JI; Dhani NC; Butler MO; Tonkin K; Tan Q; Tan DSP; Brooks K; Ramsahai J; Wang L; Pham NA; Shaw PA; Tsao MS; Garg S; Stockley T; Oza AM
Clin Cancer Res; 2018 Dec; 24(24):6168-6174. PubMed ID: 30108107
[TBL] [Abstract][Full Text] [Related]
13. Loss of ARID1A expression is related to shorter progression-free survival and chemoresistance in ovarian clear cell carcinoma.
Katagiri A; Nakayama K; Rahman MT; Rahman M; Katagiri H; Nakayama N; Ishikawa M; Ishibashi T; Iida K; Kobayashi H; Otsuki Y; Nakayama S; Miyazaki K
Mod Pathol; 2012 Feb; 25(2):282-8. PubMed ID: 22101352
[TBL] [Abstract][Full Text] [Related]
14. Genomic characterization of Chinese ovarian clear cell carcinoma identifies driver genes by whole exome sequencing.
Yang Q; Zhang C; Ren Y; Yi H; Luo T; Xing F; Bai X; Cui L; Zhu L; Ouyang J; Jiang P; Fan W; Qiu J; Wang F; Xing X; Zhang Z; Zhang X; Zhang R
Neoplasia; 2020 Sep; 22(9):399-430. PubMed ID: 32650224
[TBL] [Abstract][Full Text] [Related]
15. Serum D-dimer, albumin and systemic inflammatory response markers in ovarian clear cell carcinoma and their prognostic implications.
Chen W; Zhong S; Shan B; Zhou S; Wu X; Yang H; Ye S
J Ovarian Res; 2020 Aug; 13(1):89. PubMed ID: 32771026
[TBL] [Abstract][Full Text] [Related]
16. Demographic Clinical and Prognostic Factors of Primary Ovarian Adenocarcinomas of Serous and Clear Cell Histology-A Comparative Study.
Schnack TH; Høgdall E; Nedergaard L; Høgdall C
Int J Gynecol Cancer; 2016 Jan; 26(1):82-90. PubMed ID: 26569060
[TBL] [Abstract][Full Text] [Related]
17. Expression and significance of CD44, CD47 and c-met in ovarian clear cell carcinoma.
Wang H; Tan M; Zhang S; Li X; Gao J; Zhang D; Hao Y; Gao S; Liu J; Lin B
Int J Mol Sci; 2015 Feb; 16(2):3391-404. PubMed ID: 25658794
[TBL] [Abstract][Full Text] [Related]
18. [Clinical significance of targeting drug-based molecular biomarkers expression in ovarian clear cell carcinoma].
Li MJ; Li HR; Cheng X; Bi R; Tu XY; Liu F; Chen LH
Zhonghua Fu Chan Ke Za Zhi; 2017 Dec; 52(12):835-843. PubMed ID: 29325268
[No Abstract] [Full Text] [Related]
19. Distinct gene expression profiles associated with clinical outcomes in patients with ovarian clear cell carcinoma and high-grade serous ovarian carcinoma.
Zhou H; Liu Q; Shi X; Liu Y; Cao D; Yang J
J Ovarian Res; 2020 Apr; 13(1):38. PubMed ID: 32295618
[TBL] [Abstract][Full Text] [Related]
20. Next-generation sequencing shows the genomic features of ovarian clear cell cancer and compares the genetic architectures of high-grade serous ovarian cancer and clear cell carcinoma in ovarian and endometrial tissues.
Gan M; Tai Z; Yu Y; Zhang C; Xu J
PeerJ; 2023; 11():e14653. PubMed ID: 36721777
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
